Nurix Therapeutics’ Post

Encouraging preliminary data from Phase II trial in ALS suggesting a benefit to explore in further clinical trials. https://lnkd.in/ekvrhcsA

No convergence of Kaplan-Meier rates over time between Evolut™ #TAVI and #SAVR in low-risk patients out to 4 years. Discover the exciting clinical outcomes from the Evolut Low Risk mid-term results presented at #TCT2023 https://bit.ly/3Sgi9eg

📌NEW ISSUE OUT📌 ✅The 18th EBC consensus document; ✅Morphofunctional assessment in ACS patients; ✅OCT-guided PCI in STEMI patients; ✅A debate on bivalirudin; ✅The A-Flux − a selfexpanding coronary sinus reducer; ✅5-year outcomes of the ACURATE neo AS study; and more https://ow.ly/7Ipz50SQXTu

Valoctocogene roxaparvovec #GeneTherapy: The 3-year update on hemostatic efficacy, safety and quality of life in severe #hemophilia A patients of the 134 patients who participated in the Phase III Clinical Trial is now published! Read the full article here: https://bit.ly/4cthDQS

It's International Clinical Trials Day! The importance of Clinical Trials is definitely not lost on us at mdgroup. Clinical trials play a pivotal role in advancing medical knowledge and improving patient outcomes. The value to society is immeasurable, searching for new and innovative ways to treat, detect, and prevent disease. We are proud to be in this industry, providing remarkable support and services to patients at every clinical trial stage. #ClinicalTrialsDay2024 #ClinicalTrialsDay #ClinicalTrials

Today we announced a second positive data and safety monitoring board (DSMB) review for efzofitimod in our ongoing Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. The DSMB recommended that the study could continue without any modifications after a second pre-planned, interim analysis. Current standard of care for patients with pulmonary sarcoidosis includes oral corticosteroids, which can incur significant side effects and toxicity. Efzofitimod has the potential to be a safe, non-steroidal treatment option for these patients, which is greatly needed. Read more here: https://bit.ly/4dBVcuP

🌟 Exciting Results from TIF 2.0 Study! 85 prospective patients who underwent the TIF 2.0 procedure, with 81 included in the analysis. - Clinical success was achieved in 94% of patients. - GERD-HRQL scores improved in 89%, and elevated RSI scores normalized in 85% of patients. - Patient satisfaction improved from 8% to 79% (p <0.0001). - At baseline, 81% were taking daily PPIs, which reduced to 80% on no or occasional PPIs after TIF 2.0 (p<0.0001). - Normal esophageal acid exposure time was observed in 72%, with better outcomes linked to an optimized TIF 2.0 valve (94% vs 57%, p=0.007). -No SAE GIE 2024 Marcia Irene Canto MD, David L. Diehl, Brett Parker, Barham K. Abu Dayyeh, Jennifer M. Kolb, Michael Murray, Reem Z. Sharaiha, Olaya I. Brewer Gutierrez, Amit Sohagia, Harshit S. Khara MD, Peter Janu, Kenneth Chang #GERD #TIF2.0 #HealthcareInnovation #PatientCare #MedicalResearch

In our latest published study, #TissueCypher results for 8,080 #BarrettsEsophagus patients (from tests ordered by 891 physicians at 505 clinical sites) found high risk patients in all clinicopathologic subsets. Patients identified by TissueCypher high-risk scores had a personal risk of progression 2X higher than confirmed low-grade dysplasia. Check out our clinical summary of the data: https://lnkd.in/eN2zaYmq

The last patient visit has been completed in our phase 1b study involving patients with pain caused by herniated discs. We follow the communicated timeline and expect to present study results during the fourth quarter of 2024. CEO Andreas Gerward commented: "I am very proud that we have conducted our clinical study according to plan and have exceeded our goal regarding the number of patients who completed all their visits. We are now approaching the most exciting part – reviewing the study results. However, before that, the collected data needs to be verified and quality-checked, after which data analysis can produce and compile the results. We estimate this will take about three months. During this period, we will intensify dialogues with potential partners." Read more: https://lnkd.in/dyYZ5RPX

With its ability to detect and monitor diseases with unparalleled accuracy, immunodiagnostics stands as a cornerstone of modern medicine. Explore the impact of precision diagnostics on patient care and clinical outcomes. #Diasorin #immunodiagnostics #WorldImmunizationWeek